University of Minnesota Medical Center, Fairview
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT02162420
Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.
Looking for future studies?
Notify Me0 year–70 year
All sexes
Interventional
Not applicable
Minneapolis, Minnesota, 55455, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
Other names: Fludara
Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
TBI 200 cGy as a single fraction on day -1 from transplant.
Other names: TBI
Stem cell transplant on day 0.
Other names: HSCT
ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
Other names: Rabbit ATG
Time frame: Day 42
Incidence of neutrophil engraftment by day 42.
Time frame: 1 year
Incidence of platelet engraftment at 1 year
Time frame: Day 100
Incidence of regimen related mortality by day 100.
Time frame: Day 100
Incidence of acute graft-versus-host disease by day 100.
Time frame: 6 Months
Incidence of chronic graft-versus-host disease by 6 months
Time frame: 1 Year
Incidence of chronic graft-versus-host disease by 1 year
Time frame: 1 Year
Incidence of secondary malingancies
Masonic Cancer Center, University of Minnesota
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00455312
Anemia, Anemia, Aplastic
Minneapolis, Minnesota, United States
View Trial DetailsNCT01659606
Anemia, Anemia, Aplastic
Chicago, Illinois, United States
View Trial DetailsNCT00499070
Anemia, Anemia, Aplastic
Vienna, Austria
View Trial DetailsNCT00004787
Anemia, Anemia, Aplastic
View Trial Details